The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

The disclosure provides methods and compositions for immune dis-inhibition. In certain embodiments, the methods comprise administering an effective amount of an agent that decreases the amount of a soluble cytotoxic receptor or inhibits its activity. In certain embodiments, the agent inhibits the proliferation, growth, or survival of cancer cells, decreases the size or a tumor, or inhibits tumor growth.

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

Compositions and methods for treating diseases and disorders expressing tissue inhibitor of metalloproteinase-4 (TIMP-4) are provided.

Methods for monitoring lung inflammation status of a subject suffering from a respiratory disorder comprise determining levels of at least three markers in urine samples taken from the subject at multiple time points, wherein increased levels of at least one of the markers in a urine sample is indicative of or predictive of a pulmonary exacerbation and/or wherein decreased levels of at least one of the markers in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, a pulmonary exacerbation, wherein at least one of the markers is selected from RNASE3, Periostin, Siglec 8, chitinase-3-like protein (C3L1) and cathepsin B. Corresponding systems, test kits and computer programs are provided.

Methods for determining the presence, severity, and/or predisposition of Idiopathic Pulmonary Fibrosis (IPF) in an individual are disclosed. The methods utilize at least one diagnostic marker of a dynamic process of extracellular matrix synthesis and/or extracellular matrix degradation from said sample. The at least one diagnostic marker may be selected from the group consisting of tissue metallopeptidase inhibitor 1 (TIMP1), hyaluronan (HA), and/or Procollagen Type III N-terminal propeptide (PIIINP).

The present invention discloses a method of determining the glycoprofile of a protein, comprising (a) contacting a sample comprising said protein with first beads having coupled thereto an antibody directed against said protein, to form an antibody-protein complex, (b) contacting said antibody-protein complex with one or more further beads, each further bead having coupled thereto (i) a label which amplifies a signal being generated and (ii) a lectin, to form an antibody-protein-lectin complex; and (c) determining the glycoprofile of said protein. Further disclosed are methods for diagnosing cancer, autoimmune diseases and inflammatory diseases as well as kits for performing the methods disclosed herein.

Provided are methods and related kits for detection of early stage pancreatic ductal adenocarcinoma. Also provided are methods for treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.